Edition:
United States

Alexion Pharmaceuticals Inc (ALXN.OQ)

ALXN.OQ on NASDAQ Stock Exchange Global Select Market

123.00USD
23 Oct 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$123.00
Open
$121.96
Day's High
$124.20
Day's Low
$119.39
Volume
413,401
Avg. Vol
524,075
52-wk High
$142.14
52-wk Low
$102.21

Chart for

About

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical development programs include Soliris (eculizumab... (more)

Overall

Beta: 0.82
Market Cap(Mil.): $28,851.35
Shares Outstanding(Mil.): 222.86
Dividend: --
Yield (%): --

Financials

  ALXN.OQ Industry Sector
P/E (TTM): -- 29.75 32.14
EPS (TTM): -0.08 -- --
ROI: -0.13 13.18 12.83
ROE: -0.18 15.14 14.95

US STOCKS-Wall Street rally disintegrates shortly before the close

* Indexes: Dow Jones -0.40 pct, S&P 500 -0.33 pct, Nasdaq -0.21 pct (Adds investor comment, details on stock moves)

Sep 26 2018

US STOCKS-Health stocks lift Wall St as banks dip ahead of expected rate hike

* Indexes up: 0.22 pct, S&P 0.25 pct, Nasdaq 0.34 pct (Changes comment, updates prices, adds details)

Sep 26 2018

US STOCKS-Health shares prop up Wall St as banks dip ahead of expected rate hike

* Indexes: 0.15 pct, S&P 0.15 pct, Nasdaq 0.22 pct (Updates to open)

Sep 26 2018

Alexion to buy biotech firm Syntimmune for up to $1.2 billion

Alexion Pharmaceuticals Inc said on Wednesday it would buy privately held biotech company Syntimmune for a total value of up to $1.2 billion, bolstering its portfolio of drugs to treat rare disorders.

Sep 26 2018

UPDATE 1-Alexion to buy biotech firm Syntimmune for up to $1.2 bln

Sept 26 Alexion Pharmaceuticals Inc said on Wednesday it would buy privately held biotech company Syntimmune for a total value of up to $1.2 billion, bolstering its portfolio of drugs to treat rare disorders.

Sep 26 2018

Alexion to buy biotech firm Syntimmune for up to $1.2 bln

Sept 26 Alexion Pharmaceuticals Inc said on Wednesday it would buy privately held biotech company Syntimmune for a total value of up to $1.2 billion, giving it access to a rare blood disorder drug.

Sep 26 2018

BRIEF-Alexion Reports Q1 Results And Positive Topline Data From ALXN1210 Phase 3 PNH Switch Study

* ALEXION REPORTS FIRST QUARTER 2018 RESULTS AND POSITIVE TOPLINE DATA FROM ALXN1210 PHASE 3 PNH SWITCH STUDY

Apr 26 2018

Earnings vs. Estimates